Objectives: The VE1 monoclonal antibody was developed to recognize the V600E mutation in BRAF, which is found in various tumors. Methods: We report that the VE1 antibody stains normal anterior pituitary gland and adrenal cortex, which lack detectable BRAF V600E mutations. Results: Staining with the VE1 antibody was seen in the adenohypophysis and correlated well with adrenocorticotropic hormone (ACTH)–positive cells. ACTH-positive cells were typically most concentrated in the central mucoid wedge and pars intermedia, and VE1 staining was strong in these regions. Moreover, VE1 staining was seen in ACTH-expressing pituitary adenomas without detectable BRAF mutations. VE1 staining of the adrenal cortex wa
<p>ACTH and GH immune positivity are shown in the region of the tumor sample immunostained for β-cat...
CONTEXT: Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of ...
Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from steroidogenic...
Objective: Several reports have described antipituitary antibodies by immunofluorescent or immuno-bl...
Context: Pituitary antibodies have been measured mainly to identify patients whose disease is caused...
The ACTH receptor (ACTH-R) is the second member of the melanocortin (MC-2) receptor family that incl...
Context: Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of ...
The ACTH receptor (ACTH-R) is the second member of the melanocortin (MC-2) receptor family that incl...
Context: Limited screening suggests that three germline mutations in the aryl hydrocarbon receptor i...
Purpose: Depending on improvements in immunohistochemical and ultrastructural analyses, hormonal imm...
Background: Aldosterone-producing adrenocortical adenoma (APA) is responsible for the majority of ca...
OBJECTIVE: BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carc...
OBJECTIVE: Mutations of the gsp oncogene are responsible for 30-40% of GH-producing pituitary adenom...
Objective: In order to study clinical, histomorphological, histochemical mid inimunohistochemical ch...
OBJECTIVE: BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carc...
<p>ACTH and GH immune positivity are shown in the region of the tumor sample immunostained for β-cat...
CONTEXT: Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of ...
Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from steroidogenic...
Objective: Several reports have described antipituitary antibodies by immunofluorescent or immuno-bl...
Context: Pituitary antibodies have been measured mainly to identify patients whose disease is caused...
The ACTH receptor (ACTH-R) is the second member of the melanocortin (MC-2) receptor family that incl...
Context: Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of ...
The ACTH receptor (ACTH-R) is the second member of the melanocortin (MC-2) receptor family that incl...
Context: Limited screening suggests that three germline mutations in the aryl hydrocarbon receptor i...
Purpose: Depending on improvements in immunohistochemical and ultrastructural analyses, hormonal imm...
Background: Aldosterone-producing adrenocortical adenoma (APA) is responsible for the majority of ca...
OBJECTIVE: BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carc...
OBJECTIVE: Mutations of the gsp oncogene are responsible for 30-40% of GH-producing pituitary adenom...
Objective: In order to study clinical, histomorphological, histochemical mid inimunohistochemical ch...
OBJECTIVE: BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carc...
<p>ACTH and GH immune positivity are shown in the region of the tumor sample immunostained for β-cat...
CONTEXT: Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of ...
Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from steroidogenic...